Jennison Associates LLC Nurix Therapeutics, Inc. Transaction History

Jennison Associates LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	SELL	$12.33 - $19.81 $6,818 - $10,954	-553 Reduced 1.26%	43,181 $563,000
Q2 2022 Aug 02, 2022	SELL	$7.88 - $14.82 $165 - $311	-21 Reduced 0.05%	43,734 $554,000
Q1 2022 May 11, 2022	SELL	$12.94 - $29.65 $11.2 Million - $25.7 Million	-867,249 Reduced 95.2%	43,755 $613,000
Q4 2021 Feb 08, 2022	SELL	$26.43 - $34.5 $217,122 - $283,417	-8,215 Reduced 0.89%	911,004 $26.4 Million
Q3 2021 Nov 09, 2021	BUY	$22.71 - $36.69 $4,133 - $6,677	182 Added 0.02%	919,219 $27.5 Million
Q2 2021 Aug 12, 2021	SELL	$24.21 - $35.89 $23,168 - $34,346	-957 Reduced 0.1%	919,037 $24.4 Million
Q1 2021 May 11, 2021	BUY	$26.98 - $50.17 $19.5 Million - $36.2 Million	721,743 Added 364.06%	919,994 $28.6 Million
Q4 2020 Feb 05, 2021	SELL	$22.85 - $48.44 $43,620 - $92,471	-1,909 Reduced 0.95%	198,251 $6.52 Million
Q3 2020 Nov 04, 2020	BUY	$16.05 - $34.91 $3.21 Million - $6.99 Million	200,160 New	200,160 $6.99 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.